Farther Finance Advisors LLC Has $87,000 Position in Takeda Pharmaceutical Co. $TAK

Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 21.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,623 shares of the company’s stock after buying an additional 1,003 shares during the period. Farther Finance Advisors LLC’s holdings in Takeda Pharmaceutical were worth $87,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. acquired a new position in Takeda Pharmaceutical during the first quarter valued at approximately $51,049,000. Goldman Sachs Group Inc. lifted its stake in Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after acquiring an additional 692,404 shares during the last quarter. ABC Arbitrage SA bought a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at about $4,994,000. Crossmark Global Holdings Inc. increased its stake in shares of Takeda Pharmaceutical by 88.5% during the 1st quarter. Crossmark Global Holdings Inc. now owns 396,833 shares of the company’s stock worth $5,901,000 after purchasing an additional 186,349 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at about $2,361,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TAK shares. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Takeda Pharmaceutical in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Up 1.2%

TAK stock opened at $14.62 on Friday. The business’s fifty day moving average price is $14.84 and its two-hundred day moving average price is $14.82. The stock has a market capitalization of $46.50 billion, a price-to-earnings ratio of 48.72 and a beta of 0.21. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.